Influence of thrombolytic agents on human platelet function

G. H.R. Rao, R. F. Wilson, C. W. White, J. G. White

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

In this study, we have evaluated the effects of four different thrombolytic agents, including Streptokinase from Hoechst and from Kabivitrum, Urokinase from Abbott and tissue plasminogen activator (t-PA) from Genentech, on platelet-rich plasma clots and platelet aggregation. At concentrations lower than 50 ugs/ml, t-PA had no inhibitory effect on clot retraction or platelet aggregation induced by weak or potent agonists. At a higher concentration (> 100 ugs/ml), t-PA specifically antagonized the action of thrombin on clot formation and platelet aggregation. Streptokinase (Kabivitrum) potentiated the action of weak agonists on platelet aggregation, but the same agent from Hoechst had no negative or positive influence. None of the drugs tested had an adverse effect on platelet function at suggested therapeutic levels. None of the thrombolytic agents were capable of dissociating preformed clots made from platelet-rich plasma. However, all of them caused lysis of whole blood clots. Also, prior incubation of plasma alone or platelet-rich plasma with any of the agents prevented subsequent clot formation. The studies demonstrate that thrombolytic drugs at therapeutic concentrations do not affect platelet function adversely. They have a potent effect on whole blood clots, but not on clots from platelet-rich plasma. Therefore, platelets may play a critical role in determining the degree of reperfusion and the frequency of reocclusion following treatment with thrombolytic agents in vivo.

Original languageEnglish (US)
Pages (from-to)319-334
Number of pages16
JournalThrombosis Research
Volume62
Issue number4
DOIs
StatePublished - May 15 1991

Keywords

  • Thrombolytic agents
  • platelet function
  • streptokinase
  • tissue plasminogen activator
  • urokinase

Fingerprint Dive into the research topics of 'Influence of thrombolytic agents on human platelet function'. Together they form a unique fingerprint.

Cite this